FDA Approves Alzheimer's Blood Test Developed by Roche and Eli Lilly
By Katherine Hamilton
The Food and Drug Administration cleared a blood test for identifying Alzheimer's disease symptoms, which was developed by Roche and Eli Lilly.
The Elecsys Phospho-Tau Plasma test identifies amyloid pathology associated with Alzheimer's in people 55 years or older.
It provides positive, intermediate and negative result categories to support doctors assessing the likelihood of amyloid pathology. Results are interpreted in conjunction with clinical information and other relevant findings as part of an Alzheimer's diagnosis.
The blood test is meant to address the gap in diagnoses, as an estimated 75% of people living with dementia are undiagnosed, Roche said.
Quest Diagnostics and Labcorp both said they plan to start offering the blood test.
Labcorp, a lab services company, said the test is an important tool for clinicians to rule in or rule out amyloid pathology in people showing signs of cognitive decline. For Quest, the test will be part of its menu of blood-based Alzheimer's biomarker tests under the AD-Detect brand name.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
August 24, 2026 08:26 ET (12:26 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Companies to Invest in Now
The 10 Best Dividend Stocks
United States